BioSpace News Archive

Compugen Ltd. announced today publication of ePosters by ESMO Immuno-Oncology Congress 2022 (ESMO-IO), showing that Compugen’s COM701 (anti-PVRIG) in dual and triple combination with nivolumab ± BMS-986207 (anti-TIGIT) demonstrated preliminary durable anti-tumor activity and immune activation in patients with platinum resistant ovarian cancer with a favorable safety and toxicity profile.

EpicentRx Inc. announced today that the U.S. Patent and Trademark Office has issued Patent No. 11,510,901 with claims covering its dual anticancer and radio/chemoprotective investigational agent, RRx-001, for the reduction of toxicity prior to, during, or after exposure to radiation from anticancer therapy or nuclear incidents.

Deloitte has appointed Pete Lyons as national sector leader for the life sciences practice in the U.S. Lyons succeeds Mike DeLone.

Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology (ASH) meeting that will be held from December 10 to 13, 2022 in New Orleans, Louisiana.

Exscientia plc (Nasdaq: EXAI) today highlighted new data to identify patients that are more likely to respond to its A2A receptor antagonist, EXS-21546 (‘546) as well as the relationship to potential impact of adenosine on PD-1 inhibitor response.

Vega Therapeutics, Inc. today announced its launch and oral presentation of its first-in-class antibody therapy, VGA039, at the 64th American Society of Hematology (ASH) Annual Meeting.

BioCardia, Inc. today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure.

Virax Biolabs Group Limited announced today that their supplier has received an Emergency Use Authorization (“EUA”) from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test (the “Test”).

Click Therapeutics, Inc. today announced their partnership with The Massachusetts Medical Society (“MMS”), a statewide professional association for physicians and medical students, supporting more than 25,000 members.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases.